We describe a peptide vaccine model based on the mimicry of surface coat protein of a pathogen. This model used a macromolecular assemblage approach to amplify peptide antigens in liposomes or micelles. The key components of the model consisted of an oligomeric lysine scaffolding to amplify peptide antigens covalently 4-fold and a lipophilic membrane-anchoring group to further amplify noncovalently the antigens many-fold in liposomal or micellar form. A peptide antigen derived from the third variable domain of glycoprotein gpl20 of human immunodeficiency virus type 1 (HIV-1
Most vaccine strategy developed today against human immunodeficiency virus (HIV) infection has been directed toward the humoral response of generating neutralizing antibodies. Recent advances in mapping antigens involved in immune responses have allowed detailed characterization of epitopes that confer neutralizing, T-helper and T-cytotoxic responses (1) (2) (3) (4) (5) (6) . These developments have led to consideration of including the T-cytotoxic response along with humoral immunity in the design of peptide-based vaccines. However, traditional methods (7, 8) for preparing peptide vaccines that present peptides as macromolecules through conjugation to protein carriers or polymerization are often unable to induce cytotoxic T lymphocytes (CTL) response in vivo. Use of an adjuvant in the immunizing protocol has the advantage of enhancing the humoral response (9-11) but has mixed results in priming specific CTL response. Furthermore, the most popular adjuvant used in laboratory animals, such as Freund's complete adjuvant, is too toxic and unacceptable for humans. Ideally, protection against viral infection is best provided by both humoral and cell-mediated immunities, including long-term memory and cytotoxic T cells. In this paper, we describe a rational approach to producing a synthetic peptide-based vaccine that is effective in providing both humoral and cell-mediated immunities and safe in its exclusion of Freund's complete adjuvant. Our approach uses a macromolecular assemblage principle that allows amplification of peptide antigens to a macromolecule.
The resulting macromolecule bears the immunological mimicry of the external-surface coat protein of a pathogen.
The amplification is made possible by two synthetic components ( Fig. 1) . (i) A scaffolding consisting of an oligomeric branching lysine is used to amplify the peptide antigen 4-fold to give a multimeric structure. This covalent amplification, known as multiple antigen peptide system (MAPS), has been effective in inducing strong immune responses (12, 13) . (ii) A lipophilic membrane-anchoring moiety at the carboxyl terminus of MAPS enables further noncovalent amplification by a liposome or micellar form. Such a macromolecular assemblage will amplify the MAP antigens many-thousandfold. Several lipophilic moieties have been studied in our laboratory, the most successful is the tripalmitoyl-S-glycerylcysteine (P3C). P3C, which is a lipoamino acid from Escherichia coli, is a B cell mitogen, a nontoxic adjuvant, and can induce CTL in vivo when covalently linked to a peptide antigen (14) .
The antigen for our model is located in the third variable domain (V3 loop) of gp120, the envelope glycoprotein of HIV-1, which is the principal target for vaccine development against AIDS (4). The V3 loop of IIIB strain, amino acid sequence 291-343, contains an invariant disulfide bridge and a type-II ,3 turn with the sequence Gly-Pro-Gly at its crest. Antibodies raised to the V3 loop neutralized the in vitro infectivity of HIV, and the principal neutralizing determinant has been found to be centered at the 8 turn. Our previous studies in mice (15) have found that a 24-residue peptide of the V3 loop, referred to as B1 (sequence 308-331), contains the minimal sequence that consists of neutralizing and T-helper epitopes. In addition, this B1 sequence also contains a T-cytotoxic epitope (sequence 315-329) (6) . We show here that a vaccine model using the peptide B1 by the macromolecular assemblage approach [referred to as B1 in a tetravalent MAPS(B1M) format linked to P3C (B1M-P3C)] induces specific antibodies against gpl20 that neutralize virus infectivity in vitro and elicits CTL in vivo.
MATERIALS AND METHODS
Synthesis of BlM-P3C. Synthesis was accomplished manually by a step-wise solid-phase procedure (16) on 9-fluorenylmethoxycarbonyl (Fmoc)-Ala-OCH2-resin (17) (0.3 mmol/g of resin). After removal of the Fmoc group by 20% piperidine in dimethylformamide, the Ala-resin was coupled to a premade unit of Fmoc-Lys (P3C) ( fTo whom reprint requests should be addressed.
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contained the configuration of N-palmitoyl-S- [2,3- 
DISCUSSION
We describe here the rational design of a totally synthetic peptide-based vaccine that induces neutralizing antibody and CTL as well as a vaccine that is safer and more versatile than a whole virus or viral protein vaccine. We use a macromolecular assemblage approach to produce a multimeric form of peptide antigen, BlM-P3C, that consists of a lipophilic membrane-anchoring moiety covalently linked to a MAPS core matrix and four dendritic arms of peptide antigens derived from the V3 loop of the gpl20 envelope protein of HIV-1. Mice antisera against B1M-P3C neutralize the virus infectivity as shown by the inhibition of syncytium formation and reverse transcriptase, induce T-helper response as shown by the IL-2 production, and elicit CD8' CTL that lyse syngeneic cells expressing gpl60 on their cell surface. Furthermore, the B1M-P3C produced long-term T-cell memory, as the CTL of the immunized mice remained undiminished 5 mo after the last boost immunization (29) . These results are particularly pertinent to the development of a synthetic vaccine against AIDS because the predominant vaccine strategy has focused on neutralizing antibodies rather than cell-mediated immunity, which may be an equally effective mechanism to overcome cell-to-cell virus transmission in HIV infection. Subunit protein administered with a clinically acceptable adjuvant, such as gel of aluminium or calcium salt, is usually insufficient to elicit CTL response, particularly CD8' restricted, as shown by the results of Orentas et al. (25) , who found CD4'-specific CTL by a gpl60 subunit vaccine. Subunit vaccine expressed by live vectors, such as vaccinia virus (26) , may overcome this limitation but will need further development to define various adverse reactions in humans. The ideal vaccine may eventually be derived from the inactivated whole or attenuated virus, but the risk and long latency associated with the infection have so far limited the enthusiasm for its development.
Although synthetic peptides, in their monomeric form, possess the minimal requirement to induce immune responses, they are often insufficient to mount an effective and sustained immune response. The advantage of a multimeric over a monomeric form in vaccine design has been demonstrated and exploited by many investigators. Synthetic peptides are often polymerized by different methods to enhance immune responses (8) . Our laboratory has developed the MAPS using oligobranching lysines to present multiple cop. ies of a single peptide with good success (12, 13). Clarke et al. (24) produced a highly immunogenic preparation by presenting multiple copies of a peptide antigen using the hepatitis B core antigen. Lipid matrices, such as liposomes (10, 11) and immunostimulating complex ISCOM (9), also allow noncovalent organization of multimeric presentation of antigens on their surface. ISCOM is a stable lipid matrix that contains cholesterol and Quil A, a plant extract that also serves as an adjuvant. ISCOMs have shown immune-enhancing property superior to that of micelle (9) . Furthermore, ISCOM also has the ability to induce CTL response, as shown by Takahashi et al. (27) , who could induce CD8' CTL by immunization with purified HIV-1 envelope protein in ISCOMs. A liposome has the ability to embed the peptide antigen on its surface but is, by itself, a weak adjuvant as demonstrated in our results.
BiM in complete Freund's adjuvant elicited high and protective antibodies in mice and guinea pig (15) . In contrast, BiM, when mixed with liposomes, does not elicit significant antibody response in mice, although, with the same preparation, good but nonneutralizing antibody titers are obtained in guinea pigs. When the antigen contains a "hydrophobic foot", such as the B1M-P3C, neutralizing antibodies are obtained in both animals. The apparent difference that accounts for these results is the presence of P3C covalently linked to the antigen in these preparations. In our design, P3C, the lipophilic moiety, or hydrophobic foot, is used to serve both as a lipid anchor and an adjuvant. As a hydrophobic foot in B1M-P3C, it allows the incorporation into liposomes 40-fold more efficiently than B1M. Similar rationale has also been used by other investigators. Lowell et al.
(28) use a long-chain fatty acid as a hydrophobic foot linked to a peptide antigen to allow noncovalent complex with meningococcal outer membrane to form proteosome and multimeric forms of the peptide antigen. Jung and his colleagues (14, 18) use P3C as a built-in adjuvant of peptide antigens in many successful applications. An additional role of the lipophilic moiety is its ability to prime CTL in vivo (14) . Although peptides and proteins do not generally induce CTL response in vivo, peptides entrapped in lipid matrices or peptides containing lipophilic moieties have such a capacity. At this time the mechanism for the induction of CTL by the peptides with lipophilic associations remains unclear. Nev 
